Lillian M. Smyth

3.2k total citations
24 papers, 166 citations indexed

About

Lillian M. Smyth is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Lillian M. Smyth has authored 24 papers receiving a total of 166 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Lillian M. Smyth's work include HER2/EGFR in Cancer Research (11 papers), Advanced Breast Cancer Therapies (8 papers) and Cancer Treatment and Pharmacology (8 papers). Lillian M. Smyth is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Advanced Breast Cancer Therapies (8 papers) and Cancer Treatment and Pharmacology (8 papers). Lillian M. Smyth collaborates with scholars based in United States, Ireland and Spain. Lillian M. Smyth's co-authors include Clifford A. Hudis, David M. Hyman, Chau T. Dang, Komal Jhaveri, Neil M. Iyengar, Cristina Saura, Larry Norton, Sarina A. Piha‐Paul, Elaine M. Walsh and Séamus O’Reilly and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Lillian M. Smyth

22 papers receiving 163 citations

Peers

Countries citing papers authored by Lillian M. Smyth

Since Specialization

Citations

This map shows the geographic impact of Lillian M. Smyth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lillian M. Smyth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lillian M. Smyth more than expected).

Fields of papers citing papers by Lillian M. Smyth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lillian M. Smyth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lillian M. Smyth. The network helps show where Lillian M. Smyth may publish in the future.

Co-authorship network of co-authors of Lillian M. Smyth

This figure shows the co-authorship network connecting the top 25 collaborators of Lillian M. Smyth. A scholar is included among the top collaborators of Lillian M. Smyth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lillian M. Smyth. Lillian M. Smyth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Perspectives on the Teaching and Learning of Non-Verbal Communication Skills: Tutor, Simulated Patient and Student Experiences of a Rapid Transition to Online Learning 2026 ·Medical Science Educator ·Riemke Aggio‐Bruce, (unknown), (unknown), (unknown), (unknown), Krisztina Valter, Lillian M. Smyth	0
2	A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors 2025 ·ESMO Open ·Alison M. Schram, Naoko Takebe, (unknown), Qin Zhou, Alexia Iasonos, Jeffrey L. Silber, (unknown), (unknown), (unknown), Lillian M. Smyth, D. H. Garrison, Ecaterina E. Dumbrava	0
3	Abstract OT3-08-01: A phase 1 trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer (aBC) and other solid tumors (PIKASSO-01, trial in progress) 2023 ·Cancer Research ·Dejan Juric, Komal Jhaveri, Muralidhar Beeram, Erika Hamilton, Vincent Chau, (unknown), (unknown), Lillian M. Smyth, Funda Meric‐Bernstam	7
4	Abstract OT1-01-02: EMBER-4: A phase 3 adjuvant trial of imlunestrant vs standard endocrine therapy (ET) in patients with ER+, HER2- early breast cancer (EBC) with an increased risk of recurrence who have previously received 2 to 5 years of adjuvant ET 2023 ·Cancer Research ·Komal Jhaveri, Joyce O’Shaughnessy, Fabrice André, Matthew P. Goetz, Nadia Harbeck, (unknown), François‐Clément Bidard, Zachary M. Thomas, Suzanne R.L. Young, (unknown), Lillian M. Smyth, Michael Gnant	6
5	AKT mutant allele-specific activation dictates pharmacologic sensitivities 2022 ·Nature Communications ·Tripti Shrestha Bhattarai, Tambudzai Shamu, Alexander N. Gorelick, Matthew T. Chang, Debyani Chakravarty, (unknown), Mark T.A. Donoghue, (unknown), Swati Patel, Sizhi Paul Gao, (unknown), Sarah Phillips, Tara E. Soumerai, Wassim Abida, David M. Hyman, Alison M. Schram, David B. Solit, Lillian M. Smyth, Barry S. Taylor	26
6	Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland 2021 ·Breast Cancer Research and Treatment ·(unknown), (unknown), (unknown), (unknown), (unknown), Denis Evoy, James Geraghty, R S Prichard, Jane Rothwell, Damian McCartan, E. McDermott, Maccon Keane, Michael J. Kennedy, Séamus O’Reilly, (unknown), John Crown, Lillian M. Smyth, Catherine M. Kelly, Cecily Quinn, Janice M. Walshe	6
7	Abstract OT-09-03: EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER+ breast cancer and endometroid endometrial cancer 2021 ·Cancer Research ·Elgene Lim, M. Beeram, Amy Prawira, Amita Patnaik, (unknown), Suzanne R.L. Young, Lillian M. Smyth, Erika Hamilton	3
8	Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study 2021 ·JCO Precision Oncology ·Lillian M. Smyth, Jonathan Reichel, Jiabin Tang, Juber Patel, Fanli Meng, (unknown), Brian Houck‐Loomis, Daoqi You, Aliaksandra Samoila, Gaia Schiavon, Bob T. Li, Pedram Razavi, Salvatore Piscuoglio, Jorge S. Reis‐Filho, Barry S. Taylor, José Baselga, David B. Solit, David M. Hyman, Michael F. Berger, Sarat Chandarlapaty	4
9	173P Clinical characteristics of long-term responders to anti-HER2 therapy in metastatic breast cancer: A review of the charactHER clinical data 2020 ·Annals of Oncology ·(unknown), Naomi Walsh, Cecily Quinn, Janice M. Walshe, Lillian M. Smyth, Giuseppe Gullo, John Crown	1
10	Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland. 2020 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Denis Evoy, James Geraghty, Ruth Prichard, Jane Rothwell, Damian McCartan, Enda McDermott, Maccon Keane, John Kennedy, Séamus O’Reilly, (unknown), John Crown, Lillian M. Smyth, Catherine M. Kelly, Cecily Quinn, Janice M. Walshe	1
11	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up 2019 ·The Oncologist ·Rui Wang, Lillian M. Smyth, Neil M. Iyengar, Sarat Chandarlapaty, Shanu Modi, Maxine S. Jochelson, Sujata Patil, Larry Norton, Clifford A. Hudis, Chau T. Dang	6
12	Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer 2019 ·Annals of Oncology ·Lillian M. Smyth, Cristina Saura, Sarina A. Piha‐Paul, Janice Lu, Ingrid A. Mayer, (unknown), Iben Spanggaard, Mónica Arnedos, Richard E. Cutler, David M. Hyman	15
13	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer 2019 ·JAMA Network Open ·Neil M. Iyengar, Lillian M. Smyth, Diana Lake, Ayca Gucalp, Jasmeet Singh, Tiffany A. Traina, Patricia DeFusco, Monica Fornier, Shari Goldfarb, Komal Jhaveri, Shanu Modi, Tiffany A. Troso-Sandoval, Sujata Patil, Gary A. Ulaner, Maxine S. Jochelson, Larry Norton, Clifford A. Hudis, Chau T. Dang	6
14	Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers 2018 ·Annals of Surgical Oncology ·Patricia A. Cronin, Anya Romanoff, Emily C. Zabor, Michelle Stempel, Anne Eaton, Lillian M. Smyth, Alice Y. Ho, Monica Morrow, Mahmoud El‐Tamer, Mary L. Gemignani	8
15	PRECISE: A clinical-grade automated molecular eligibility screening and just-in-time (JIT) physician decision support solution for molecularly-selected oncology trials. 2018 ·Journal of Clinical Oncology ·Jessica J. Tao, Michael Eubank, (unknown), (unknown), Alexander Drilon, James J. Harding, Alison M. Schram, Lillian M. Smyth, Komal Jhaveri, Bob T. Li, Debyani Chakravarty, Ahmet Zehir, Michael F. Berger, Nikolaus Schultz, (unknown), Stacy B. Thomas, Peter D. Stetson, Stuart M. Gardos, David M. Hyman	1
16	Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer. 2018 ·Journal of Clinical Oncology ·Rui Wang, Lillian M. Smyth, Neil M. Iyengar, Shanu Modi, Sarat Chandarlapaty, Sujata Patil, Larry Norton, José Baselga, Clifford A. Hudis, Chau T. Dang	1
17	Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy 2016 ·Annals of Oncology ·Neil M. Iyengar, Lillian M. Smyth, Diana Lake, Ayca Gucalp, (unknown), (unknown), Patricia DeFusco, (unknown), Monica Fornier, Shari Goldfarb, Komal Jhaveri, Asma Latif, Shanu Modi, Tiffany A. Troso-Sandoval, Gary A. Ulaner, Maxine S. Jochelson, José Baselga, Larry Norton, C. Hudis, Chau T. Dang	2
18	Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study 2016 ·Breast Cancer Research and Treatment ·Lillian M. Smyth, Neil M. Iyengar, (unknown), (unknown), Sujata Patil, (unknown), (unknown), Jasmeet Singh, Sarat Chandarlapaty, S. Sugarman, Elizabeth Comen, Pamela Drullinsky, Tiffany A. Traina, Tiffany A. Troso-Sandoval, José Baselga, Larry Norton, Clifford A. Hudis, Chau T. Dang	20
19	Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland 2015 ·Breast Cancer Research and Treatment ·Lillian M. Smyth, (unknown), Elaine M. Walsh, Catherine M. Kelly, Maccon Keane, Esther M. John, Liam Grogan, Bryan T. Hennessy, Séamus O’Reilly, Linda Coate, Miriam O’Connor, Cecily Quinn, (unknown), (unknown), Janice M. Walshe	29
20	Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result. 2015 ·Journal of Clinical Oncology ·Lillian M. Smyth, Neil M. Iyengar, Sarat Chandarlapaty, Steven Sugarman, Elizabeth Comen, Pamela Drullinsky, Nancy T. Sklarin, Tiffany A. Traina, Tiffany A. Troso-Sandoval, Sujata Patil, (unknown), (unknown), José Baselga, Larry Norton, Clifford A. Hudis, Chau T. Dang	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact